髓过氧化物酶抑制减轻中性粒细胞活化、ANCA介导的内皮损伤及新月体性肾小球肾炎
该研究探讨髓过氧化物酶抑制剂AZM198对ANCA相关血管炎及新月体性GN的作用。体外实验显示AZM198减少中性粒细胞胞外诱捕器形成、活性氧产生和中性粒细胞脱颗粒,并减轻内皮细胞损伤;在鼠类模型中延迟治疗显著降低蛋白尿、肾小球血栓形成、血肌酐和肾小球巨噬细胞浸润,且不增加适应性T细胞反应。提示MPO抑制可能成为新月体性GN的辅助治疗新策略。
要点
- 新月体性GN活检标本均存在肾小球细胞外MPO沉积,且与eGFR和新月体形成显著相关。
- AZM198在体外显著减少ANCA刺激的中性粒细胞NETs形成、ROS产生和HNP释放,并减轻内皮细胞损伤。
- 在鼠类肾毒血清肾炎模型中,延迟AZM198治疗显著降低蛋白尿、肾小球血栓、血肌酐和巨噬细胞浸润,不增加T细胞反应。
核心结论
- 髓过氧化物酶抑制可减少ANCA相关血管炎患者的中性粒细胞脱颗粒及中性粒细胞介导的内皮损伤。
- 在临床前新月体性GN中,延迟MPO抑制可减轻肾脏损伤而不增强适应性免疫反应,提示其可能成为新型辅助治疗。
研究设计与样本
- 研究评估了不同形式新月体性GN患者的肾活检标本中MPO和中性粒细胞,检测了ANCA相关血管炎患者及对照的血清MPO浓度。
- 体外实验检测AZM198对ANCA刺激的中性粒细胞NET形成、ROS产生、脱颗粒及内皮细胞损伤的影响。
- 在鼠类肾毒血清肾炎模型中测试AZM198对新月体性GN严重程度及抗原特异性T细胞反应的影响。
主要发现
- 所有新月体性GN活检标本均有肾小球细胞外MPO沉积,且与eGFR和新月体形成显著相关。
- 体外AZM198显著减少中性粒细胞NET形成、ROS产生和释放的人中性粒细胞肽水平,并减轻中性粒细胞介导的内皮细胞损伤。
- 体内延迟AZM198治疗显著降低蛋白尿、肾小球血栓形成、血清肌酐和肾小球巨噬细胞浸润,且不增加适应性T细胞反应。
关键数值与推荐
- 新月体性GN活检标本中细胞外肾小球MPO沉积与eGFR及新月体形成显著相关。
- AZM198在体外显著减少ANCA刺激的中性粒细胞NET形成、ROS产生和HNP释放。
- 在鼠类模型中,延迟AZM198治疗显著降低蛋白尿、肾小球血栓、血清肌酐和肾小球巨噬细胞浸润。
临床怎么用
- MPO抑制可能作为新月体性GN的辅助治疗策略,尤其适用于ANCA相关血管炎患者。
- 需进一步临床研究验证AZM198在新月体性GN患者中的疗效和安全性。
局限性
- 研究主要为体外实验和临床前鼠类模型,尚未在患者中进行治疗验证。
- 原文未报告样本量、具体数值、P值等详细统计信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Myeloperoxidase released after neutrophil and monocyte activation can generate reactive oxygen species, leading to host tissue damage. Extracellular glomerular myeloperoxidase deposition, seen in ANCA-associated vasculitis, may enhance crescentic GN through antigen-specific T and B cell activation. Myeloperoxidase-deficient animals have attenuated GN early on, but augmented T cell responses. We investigated the effect of myeloperoxidase inhibition, using the myeloperoxidase inhibitor AZM198, to understand its potential role in treating crescentic GN. METHODS: We evaluated renal biopsy samples from patients with various forms of crescentic GN for myeloperoxidase and neutrophils, measured serum myeloperoxidase concentration in patients with ANCA-associated vasculitis and controls, and assessed neutrophil extracellular trap formation, reactive oxygen species production, and neutrophil degranulation in ANCA-stimulated neutrophils in the absence and presence of AZM198. We also tested the effect of AZM198 on ANCA-stimulated neutrophil-mediated endothelial cell damage in vitro, as well as on crescentic GN severity and antigen-specific T cell reactivity in the murine model of nephrotoxic nephritis. RESULTS: All biopsy specimens with crescentic GN had extracellular glomerular myeloperoxidase deposition that correlated significantly with eGFR and crescent formation. In vitro, AZM198 led to a significant reduction in neutrophil extracellular trap formation, reactive oxygen species production, and released human neutrophil peptide levels, and attenuated neutrophil-mediated endothelial cell damage. In vivo, delayed AZM198 treatment significantly reduced proteinuria, glomerular thrombosis, serum creatinine, and glomerular macrophage infiltration, without increasing adaptive T cell responses. CONCLUSIONS: Myeloperoxidase inhibition reduced neutrophil degranulation and neutrophil-mediated endothelial cell damage in patients with ANCA-associated vasculitis. In preclinical crescentic GN, delayed myeloperoxidase inhibition suppressed kidney damage without augmenting adaptive immune responses, suggesting it might offer a novel adjunctive therapeutic approach in crescentic GN.
引用
- Antonelou M, Michaëlsson E, Evans RDR, et al. Therapeutic Myeloperoxidase Inhibition Attenuates Neutrophil Activation, ANCA-Mediated Endothelial Damage, and Crescentic GN. J Am Soc Nephrol. 2019. PMID: 31879336. doi:10.1681/ASN.2019060618
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。